Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  Hindorf, Cecilia ^a,b   Lindén, Ola ^a   Stenberg, Lars ^a   Tennvall, Jan ^a   Strand, Sven Erik ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIATRIZOATE; EPRATUZUMAB; EPRATUZUMAB IN 111; EPRATUZUMAB Y 90; UNCLASSIFIED DRUG;

ADULT; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE CALCULATION; DOSIMETRY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TARGETING; HUMAN; IMAGE ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; DOSE FRACTIONATION; HUMANS; LYMPHOMA; MODELS, STATISTICAL; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 0141791402     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Thomas, S. R., Stabin, M. G., Chen, C-T., and Samaratunga, R. C. MIRD Pamphlet No. 14 revised: a dynamic urinary bladder model for radiation dose calculations. J. Nucl. Med., 40: 102s-123s, 1999.
2. Bergqvist, L., Strand, S-E., Persson, B., Hafström, L., and Jönsson, P-E. Dosimetry in lymphoscintigraphy of Tc-99m antimony sulfide colloid. J. Nucl. Med., 23: 698-705, 1982.
3. Grafström, G., Strand, S-E., Kontestabile, E., Almén, A., Bergqvist, L., and Larsson, I. Extravasation of radiopharmaceuticals. A study of its frequency and estimation of absorbed doses in diagnosis and therapy. In: Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge Associated Universities, pp. 522-531, 1999.
4. Howell, R. W., Narra, V. R., and Rao, D. V. Absorbed dose calculations for rapidly growing tumors. J. Nucl. Med., 33: 277-281, 1992.
5. ICRU Report 67. Absorbed dose specification in nuclear medicine. J. ICRU, 2: 2002.
6. Thomas, S. R., Maxon, H. R., and Kereiakes, J. G. In vivo quantitation of lesion radioactivity using external counting methods. Med. Phys., 3: 253-255, 1976.
7. Siegel, J. A., Thomas, S. R., Stubbs, J. B., Stabin, M. G., Hays, M. T., Koral, K. F., Robertson, J. S., Howell, R. W., Wessels, B. W., Fisher, D. R., Weber, D. A., and Brill, A. B. MIRD Pamphlet No. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J. Nucl. Med., 40: 37s-61s, 1999.
8. Stabin, M. G. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med., 37: 538-546, 1996.
9. Richaud, P. M., Soubeyran, P., Eghbali, H., Chacon, B., Marit, G., Broustet, A., and Hoerni, B. Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma: results of a pilot study. Int. J. Radiat. Oncol. Biol. Phys., 40: 387-390, 1998.
10. DeNardo, S. J., DeNardo, G. L., O'Grady, L. F., Macey, D. J., Mills, S. L., Epstein, A. L., Peng, J-S., and McGahan, J. P. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int. J. Biol. Markers, 2: 49-53, 1987.
11. 131I-LYM-1 antibody. Cancer Biother. Radiopharm., 13: 239-254, 1998.
12. Illidge, T. M., Cragg, M. S., McBride, H. M., French, R. R., and Glennie, M. J. The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma. Blood, 94: 233-243, 1999.
13. McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., and Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 16: 2825-2833, 1998.
14. Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., and Timmerman, J. Immunotherapy of non-Hodgkin's lymphoma. Hematology, 221-240, 2001.
15. Davis, T. A., and Kaminski, M. S. Results of a randomized study of Bexxar (tositumomab and iodine 131 tositumomab) vs. unlabeled tositumomab in patients with relapsed or refractory low-grade of transformed non-Hodgkin's lymphoma (NHL). Blood, 98: 843, 2001.